Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.509NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.293ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
B.1.293ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
B.1.293ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
B.1.293NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.225ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
B.1.1.225ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
B.1.1.225ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
B.1.1.225NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.637ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
B.1.637ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-4083.33China
B.1.637ENiu-ECACGTTAACAATATTGCAGC20402639126372R-3779.86China
B.1.637NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.39 (Delta)ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
AY.39 (Delta)ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
AY.39 (Delta)ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
AY.39 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.26 (Delta)ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
AY.26 (Delta)ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
AY.26 (Delta)ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
AY.26 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.103 (Delta)ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
AY.103 (Delta)ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
AY.103 (Delta)ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
AY.103 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.3 (Delta)ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
AY.3 (Delta)ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
AY.3 (Delta)ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
AY.3 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.18.7ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-802.098France
JN.1.18.7ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
JN.1.18.7ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
JN.1.18.7NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
MB.1ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
MB.1ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
MB.1ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
MB.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
LE.1ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
LE.1ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
LE.1ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
LE.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
XBB.1.5ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
XBB.1.5ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
XBB.1.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
LF.3ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
LF.3ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
LF.3ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
LF.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
MD.1.1ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used